Chapter 2 of 25
What you will learn
- Recognize bleeding patterns that need assessment.
- Separate a prompt appointment from an emergency.
- Understand why persistent symptoms matter after a reassuring test.
Bleeding after menopause
Postmenopausal bleeding means bleeding after at least 12 months without periods due to natural menopause. It includes a single spot, pink or brown discharge, or a larger bleed. Do not wait for another episode before arranging assessment. Common explanations include thinning vaginal or uterine tissues, polyps and medication effects, but a clinician needs to consider precancer and cancer.
If you use menopausal hormone therapy, the expected bleeding pattern depends on the regimen and when it started. New, persistent or unexpected bleeding still needs review. Anticoagulants can worsen bleeding, but they should not automatically be assumed to be its only cause. Do not stop prescribed hormones or blood thinners on your own; contact the prescriber and describe the change.
Before menopause
Warning patterns include bleeding between periods, periods that become unusually heavy or prolonged, and irregular bleeding that persists. Polycystic ovary syndrome and other causes of infrequent ovulation can make cycles irregular, but a new pattern should not simply be dismissed as “the usual hormones.” Pregnancy-related causes and other gynaecological conditions also need consideration where relevant.
Younger age does not make endometrial cancer impossible. The decision to sample the lining depends on age, persistence, risk factors and response to initial treatment. A clinician may recommend a biopsy in a younger person with prolonged abnormal bleeding, especially with chronic anovulation or other risks. There is no single menstrual pattern that diagnoses cancer.
Other symptoms
Watery, blood-stained or unusual vaginal discharge can occur. Pelvic pressure, persistent pain, abdominal swelling, changes in bladder or bowel function, or unexplained weight loss may require investigation. These symptoms are not specific to endometrial cancer. Their duration, progression and associated findings help the team decide what tests are useful.
Symptoms can be absent or subtle. A lack of pain does not mean bleeding is harmless. Conversely, pain alone does not establish cancer or its stage. An educational symptom tool cannot replace examination and tissue testing.
What a current assessment may involve
ACOG's April 2026 update recommends transvaginal ultrasound together with endometrial tissue sampling for most patients with postmenopausal bleeding. Ultrasound alone can still be appropriate in selected low-risk circumstances after a single episode, with a fully visualized lining no thicker than 4 mm and reliable access to prompt reassessment. This is a clinician's decision, not a rule to apply to your own scan.
Persistent or recurrent bleeding warrants re-evaluation even after a thin lining or a benign biopsy. An inadequate sample is not the same as a negative result. A focal polyp or lesion can require hysteroscopy to see and sample the area directly. National pathways and access vary, but ongoing symptoms should not disappear into a routine screening schedule.
When to seek urgent help
| Situation | Sensible action |
|---|---|
| Heavy ongoing bleeding with faintness, marked weakness or breathlessness | Seek emergency assessment |
| Severe sudden pain, collapse or possible pregnancy with significant bleeding | Seek urgent emergency care |
| Any postmenopausal spotting while otherwise stable | Arrange prompt medical assessment |
| Repeated bleeding after a reassuring test | Contact the team for re-evaluation |
Questions and take-home messages
Should I wait until my next Pap test? No; cervical screening does not investigate the uterine lining. What should I record? Dates, amount, pain, discharge and relevant medicines can help, but do not delay care to complete a diary. Ask how results will arrive and whom to contact if bleeding continues.
Related chapters
References and review status
- ACOG updated postmenopausal bleeding guidance, April 2026
- NCI: Endometrial Cancer Treatment, patient version
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy